Part I of the study will consist of a single-dose, open-label, randomized, four-way cross over study with topical administration of etoricoxib gel on the knee of osteoarthritis participants. The washout between successive dose administrations will be at least one week. Part 2 of the study will consist of double-blind, randomized, placebo-controlled, parallel groups, multiple dose, four times daily topical administration of etoricoxib or placebo gel on the knee of osteoarthritis participants for a period of two weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01980940?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
